FINWIRES · TerminalLIVE
FINWIRES

$BBIO

8 stories mentioning BBIO

Every FINWIRES story that references BBIO, newest first.

Insider Trading

BridgeBio Pharma Insider Sold Shares Worth $5,413,289, According to a Recent SEC Filing

Neil Kumar, Director, Chief Executive Officer, on June 04, 2026, sold 80,000 shares in BridgeBio Pharma (BBIO) for $5,413,289. Following the Form 4 filing with the SEC, Kumar has control over a total of 4,561,774 common shares of the company, with 243,327 shares held directly and 4,318,447 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1743881/000147083126000523/xslF345X05/wk-form4_1780956089.xml

$BBIO
Research

Canaccord Genuity Initiates BridgeBio Pharma at Buy With $104 Price Target

BridgeBio Pharma (BBIO) has an average rating of buy and mean price target of $104.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$BBIO
Insider Trading

Bridgebio Pharma Insider Sold Shares Worth $1,812,522, According to a Recent SEC Filing

Neil Kumar, Director, Chief Executive Officer, on May 21, 2026, sold 26,103 shares in Bridgebio Pharma (BBIO) for $1,812,522. Following the Form 4 filing with the SEC, Kumar has control over a total of 5,157,460 common shares of the company, with 243,327 shares held directly and 4,914,133 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1743881/000147083126000488/xslF345X05/wk-form4_1779828852.xml

$BBIO
Wire

BridgeBio Pharma Shares Fall After Raymond James Downgrade

BridgeBio Pharma (BBIO) shares were down 2.5% in Tuesday trading after Raymond James downgraded the company's stock to market perform from outperform.Trading volume stood at over 1.4 million shares, against a daily average of about 2.4 million.Price: $67.37, Change: $-1.75, Percent Change: -2.53%

$BBIO
Research

Raymond James Downgrades BridgeBio Pharma to Market Perform From Outperform

BridgeBio Pharma (BBIO) has an average rating of buy and mean price target of $105.26, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$BBIO
Insider Trading

Bridgebio Pharma Insider Sold Shares Worth $671,456, According to a Recent SEC Filing

Randal W. Scott, Director, on May 15, 2026, sold 10,000 shares in Bridgebio Pharma (BBIO) for $671,456. Following the Form 4 filing with the SEC, Scott has control over a total of 15,589 common shares of the company, with 11,589 shares held directly and 4,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1743881/000147083126000470/xslF345X05/wk-form4_1779222325.xml

$BBIO
Sectors

Sector Update: Healthcare Stocks Advance Premarket Tuesday

Healthcare stocks were advancing premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.6% higher.Sionna Therapeutics (SION) shares were down more than 5% after the company reported a wider-than-expected Q1 net loss.Alkermes (ALKS) said a late-stage trial evaluating its investigational Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and key secondary endpoints. Alkermes stock was up more than 2% pre-bell.BridgeBio Pharma (BBIO) shares were up more than 1% after the company said it has submitted a new drug application to the US Food and Drug Administration for encaleret, a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic condition affecting calcium levels.

$ALKS$BBIO$IBB$SION$XLV
Sectors

Sector Update: Health Care Stocks Mixed Late Afternoon

Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index adding 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) easing 0.1%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, STAAR Surgical (STAA) needs to show that the rebound in China is sustainable after the firm reported much higher preliminary Q1 net sales than consensus, Wedbush said in a note. Wedbush raised the company's price target to $26 from $21, while keeping its neutral rating. STAAR shares jumped 21%.Amazon.com's (AMZN) Amazon Pharmacy said Thursday it is offering Eli Lilly's (LLY) obesity pill Foundayo. Additionally, WW International (WW) said Thursday it is now offering access to Foundayo for weight loss through its Med+ program and affiliated medical groups. Lilly shares rose 0.4%.BridgeBio Pharma (BBIO) is transitioning from a single-asset transthyretin story into a diversified rare disease company, with growth poised to accelerate beyond its ATTR franchise, RBC Capital said in a note. RBC started coverage of the company with an outperform rating and a price target of $100. BridgeBio shares rose 2.7%.Vanda Pharmaceuticals (VNDA) said Thursday it is calling on the US Food and Drug Administration to withdraw a proposal in the regulator's fiscal 2027 Congressional Budget Justification that would extend drug review timelines. Vanda shares were down 0.3%.

$BBIO$LLY$STAA$VNDA